Trial Profile
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Marizomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Nereus Pharmaceuticals; Triphase Accelerator Corporation
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 23 Mar 2016 Results (n=68) from the phase I part of the study published in the Blood.
- 22 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.